FDA Grants Breakthrough Therapy and Fast Track to Norroy's CAIX-Targeted PET Agent 68Ga-NYM096 in Clear Cell Kidney Cancer

Norroy claims a first for China

Norroy said Fast Track status gives it more frequent contact with the agency, added regulatory guidance during development and possible eligibility for rolling review of a New Drug Application. The Breakthrough Therapy grant, by the company's account, recognizes preliminary clinical data suggesting the agent could offer meaningful advantages over current diagnostic approaches in clear cell renal cell carcinoma. Norroy also called it the first radiopharmaceutical originating in China to receive Breakthrough Therapy designation, a claim the announcement leaves unsourced.

Founder and CEO Peng Fang said the company plans "to initiate Phase I clinical trials evaluating 68Ga-NYM096 in both China and the United States." No start date accompanies either. Nothing in the release quantifies the "promising clinical data" Fang cited, and the company did not say how many patients have been imaged or what reading criteria were used.

Three registry entries, one Beijing hospital

Peking Union Medical College Hospital is the listed sponsor of every registered study of the agent. The imaging study closest to the designated use, NCT06949215, opened in May 2025 and plans 70 presurgical patients with complex cystic renal lesions. Its primary outcome calls a lesion PET positive when its maximum standardized uptake value exceeds that of liver, then measures that call against the histology of the resected specimen classified by WHO criteria. A second study, NCT07144748, began in August 2025 and plans 120 patients across several tumor types.

A third entry covers the therapeutic half of the pair. NCT06649682, a 20-patient Phase 1 combining 68Ga-NYM096 imaging with 177Lu-NYM096 treatment in metastatic disease, has been suspended, with a registry note posted at the end of December 2025 citing concern about a stomach adverse effect at the first dose of the therapeutic after one patient developed grade 3 radiation-induced gastritis. Neither the designations nor the announcement addresses that program.

The other CAIX imaging agent in front of the agency

Telix Pharmaceuticals is further along the same target and still short of approval. Its candidate, Zircaix (89Zr-girentuximab senvedoxam), is an antibody rather than a small tracer, and the company told investors in half-year results dated Aug. 20 that it received a corrected Complete Response Letter on April 10, 2026, then obtained an extension of the deadline to resubmit its biologics license application. Telix describes CAIX as heavily expressed on the surface of most clear cell tumors and largely absent from normal kidney tissue, and markets the idea of CAIX imaging as a way to cut unnecessary biopsies.

Why This Matters to the APO|APE Reader

Norroy says it holds six IND clearances from the FDA and six IND approvals from China's National Medical Products Administration across more than 10 disease targets, which makes 68Ga-NYM096 an early test of how fast a Chinese radiopharmaceutical developer can move a diagnostic through a US pathway. The first figures anyone outside the company will see are promised for the EANM Annual Congress, held Oct. 17 to 21 at the Austria Center Vienna. Until then, the call on an indeterminate renal mass ends where the Chinese study design puts it, on the pathologist's bench after surgery.